Nano-structure nasal cavity hemostat with support type medicine and instrument combination
Through a nanostructured nasal hemostasis combined with stent-type medicine and equipment, the limitations and side effects of existing nasal hemostasis methods are solved through components such as inflatable airbags, hemostasis gauze and hemostasis sponge, and a safe, effective and convenient nasal hemostasis effect is achieved.
Patent Information
- Application Number
- CN202322998053.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-06
- Publication Date
- 2025-02-14
- Estimated Expiration
- 2033-11-06
AI Technical Summary
Existing nasal hemostasis methods have limitations and side effects, such as compression and halting of hemostasis can easily cause nasal infection and hypoxia, drug halting can easily cause allergic reactions or drug residues, electrocoagulation can easily cause nasal scars or perforations, arterial embolization can easily cause intracranial complications wait.
A nanostructured nasal hemostasis using a combination of stent-type medicine and equipment, the material includes an inflatable airbag, hemostasis gauze, hemostasis sponge and a metal stent with shape memory properties. The inflatable airbag adjusts pressure and position through the inflatable valve and syringe. The hemostatic gauze and sponge have good biocompatibility and degradability, which can quickly absorb blood and promote coagulation.
It achieves effective nasal hemostasis, avoids nasal infection and scar formation, and has convenient regulation and monitoring functions to adapt to different nasal morphology and bleeding sites.
Smart Images
Figure CN222466990U_ABST
Abstract
Description
Technical Field
[0001] The utility model relates to the technical field of medical devices, and in particular to a nanostructured nasal hemostat of a stent-type drug-device combination. Background Art
[0002] Nosebleed is a common clinical problem, which can be life-threatening in severe cases. Commonly used methods for nasal hemostasis include compression hemostasis, cold compress hemostasis, drug hemostasis, electrocoagulation hemostasis, arterial embolization, etc., but these methods have certain limitations and side effects. For example, compression hemostasis is prone to cause nasal infection and hypoxia, cold compress hemostasis is prone to cause reflex vasodilation, drug hemostasis is prone to cause allergic reactions or drug residues, electrocoagulation hemostasis is prone to cause nasal scarring or perforation, and arterial embolism is prone to cause intracranial complications. Therefore, it is urgent to develop a safe, effective and convenient nasal hemostatic material. Utility Model Content
[0003] The utility model provides a nanostructured nasal hemostat of a stent-type drug-device combination. The material has good hemostatic effect, biocompatibility and degradability, can effectively prevent nasal infection and scar formation, and can conveniently adjust the pressure and position of the inflatable airbag to adapt to different nasal morphologies and bleeding sites.
[0004] A nanostructured nasal hemostatic device of a stent-type drug-device combination, comprising an inflatable airbag, characterized in that: the outer side of the inflatable airbag is covered with a stent, and the outer side of the stent is provided with a hemostatic gauze;
[0005] A hemostatic sponge is arranged between the hemostatic gauze and the bracket.
[0006] As a further limitation of the present technical solution, one end of the inflatable airbag is a plane, and the other end is an arc-shaped surface, a fixing ring is fixed at the center of one end of the plane of the inflatable airbag, one end of a connecting tube is fixedly connected inside the fixing ring, and one end of the connecting tube is fixedly connected to the inflatable airbag.
[0007] As a further limitation of the present technical solution, the other end of the connecting conduit is fixedly connected to one end of the sensing airbag, and the other end of the sensing airbag is provided with an inflation valve.
[0008] As a further limitation of the present technical solution, the inflation valve is matched with a syringe.
[0009] As a further limitation of the present technical solution, the hemostatic gauze is collagen hemostatic gauze, and the surface of the hemostatic gauze is covered with antibacterial and anti-inflammatory drugs.
[0010] As a further limitation of the present technical solution, the bracket is a metal with shape memory properties.
[0011] As a further limitation of the present technical solution, the hemostatic sponge is a degradable hemostatic sponge made of chitosan with a nanostructure and has the function of absorbing blood and promoting blood coagulation.
[0012] As a further limitation of the technical solution, a flying wing is provided between the connecting conduit and the sensing airbag.
[0013] Compared with the prior art, the advantages and positive effects of the utility model are:
[0014] It can effectively stop nasal bleeding, and has good biocompatibility and degradability, and will not cause nasal infection and scar formation;
[0015] The pressure and position of the inflatable airbag can be easily adjusted through the inflation valve and syringe to adapt to different nasal cavity shapes and bleeding sites. At the same time, the pressure change of the inflatable airbag can be monitored in real time through the sensing airbag to prevent over-inflation or leakage.
[0016] It uses a metal stent with shape memory properties, which can automatically bend to adapt to the curvature of the nasal cavity when the inflatable balloon is inflated;
[0017] It uses a chitosan hemostatic sponge with a nanostructure, which can quickly absorb blood and promote coagulation. It also has good biodegradability and biocompatibility and will not remain in the nasal cavity.
[0018] It uses recombinant collagen hemostatic gauze, which can effectively stop bleeding and protect the wound surface. It has good biodegradability and biocompatibility. It is also covered with antibacterial and anti-inflammatory drugs, which can prevent and treat nasal infections and inflammations. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The drawings described herein are used to provide a further understanding of the present application and constitute a part of the present application. The illustrative embodiments of the present application and their descriptions are used to explain the present application and do not constitute an improper limitation on the present application. Obviously, the drawings described below are only some embodiments of the present utility model. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work. In the drawings:
[0020] Figure 1 It is a three-dimensional structural schematic diagram of the first embodiment of the utility model;
[0021] Figure 2 It is a schematic diagram of the three-dimensional structure of the second embodiment of the utility model.
[0022] In the figure: 1. hemostatic gauze, 2. hemostatic sponge, 3. bracket, 4. inflatable airbag, 5. fixing ring, 6. connecting catheter, 7. flying wing, 8. induction airbag, 9. inflation valve, 10. syringe. DETAILED DESCRIPTION
[0023] The following is combined with Figure 1-Figure 2 The utility model is further described with implementation modes.
[0024] Embodiment 1: A nanostructured nasal hemostatic device of a stent-type drug-device combination, comprising an inflatable airbag 4, the outer side of the inflatable airbag 4 is covered with a stent 3, and the outer side of the stent 3 is provided with a hemostatic gauze 1;
[0025] A hemostatic sponge 2 is arranged between the hemostatic gauze 1 and the bracket 3 .
[0026] One end of the inflatable airbag 4 is a plane, and the other end is an arc-shaped surface. A fixing ring 5 is fixed at the center of one end of the plane of the inflatable airbag 4. One end of a connecting conduit 6 is fixedly connected inside the fixing ring 5. One end of the connecting conduit 6 is fixedly connected to the inflatable airbag 4.
[0027] The connecting conduit 6 can be made of a transparent or translucent material, such as polyethylene or polypropylene.
[0028] The other end of the connecting catheter 6 is fixedly connected to one end of the sensing airbag 8, and the other end of the sensing airbag 8 is provided with an inflation valve 9, and the inflation valve 9 is used for inflation. The sensing airbag 8 is used to sense the pressure in the nasal cavity. The sensing airbag 8 can expand or contract according to the pressure change in the nasal cavity, thereby feeding back to the medical staff.
[0029] The inflation valve 9 is matched with a syringe 10, and medical staff can use the syringe 10 to fill or discharge gas into the sensing airbag 8. The gas enters the inflation airbag 4 from the sensing airbag 8 through the connecting catheter 6, thereby adjusting the tension of the stent 1. The syringe 10 is used to provide a gas source, such as air or nitrogen. The syringe 10 can be composed of a conventional medical syringe or other similar devices.
[0030] The hemostatic gauze 1 is a recombinant collagen hemostatic gauze. The surface of the hemostatic gauze 3 is coated with antibacterial and anti-inflammatory drugs, such as iodine or chlorhexidine. Collagen is a natural hemostatic agent that can interact with platelets to form a gel-like hemostatic layer and provide a moist healing environment. Antibacterial and anti-inflammatory drugs can kill or inhibit the growth of bacteria and prevent infection and inflammation.
[0031] The stent 3 is a metal with shape memory properties, and the metal may be a nickel-titanium alloy. The length and diameter of the stent 1 may be designed according to different nasal cavity sizes, for example, a length of 3-5 cm and a diameter of 0.5-1 cm.
[0032] The hemostatic sponge 2 is a degradable hemostatic sponge made of chitosan with a nanostructure, which has the function of absorbing blood and promoting blood coagulation. The hemostatic sponge is wrapped in the outer layer of the stent 1, such as Figure 1 As shown, chitosan has a porous network structure with a pore size of tens to hundreds of nanometers. This structure can increase the surface area and water absorption, thereby absorbing a large amount of blood and promoting coagulation. Chitosan also has good biocompatibility and biodegradability and will not remain in the nasal cavity.
[0033] The working principle of the utility model is:
[0034] When in use, the nanostructured nasal hemostatic device of the stent-type drug-device combination is gently inserted into the nasal cavity at the bleeding site;
[0035] After insertion, inject a proper amount of air into the inflatable airbag 4 through the syringe 10 to expand it and make it close to the nasal cavity wall, and at the same time observe the pressure change of the sensing airbag 8 to avoid over-inflation or air leakage;
[0036] After hemostasis, air is pumped out of the inflatable balloon 4 through the syringe 10 to shrink it and loosen it from the nasal wall, and the inflatable balloon 4 is gently pulled out, and the bracket 3 is left in the nasal cavity to support the nasal hemostatic sponge 2 and the hemostatic gauze 1. After the inflatable balloon 4 is taken out, the patient can breathe freely;
[0037] The inflatable airbag 4 is wrapped with gauze and sponge to form a moist healing environment, which is easy to take out. When taking it out, the inflatable airbag 4 is gently pulled out along the original path without causing secondary bleeding or injury.
[0038] Embodiment 2: Based on the nanostructured nasal hemostat of a stent-type drug-device combination provided in the first embodiment of the present application, the second embodiment of the present application proposes another nanostructured nasal hemostat of a stent-type drug-device combination. The second embodiment is only a preferred embodiment of the first embodiment, and the implementation of the second embodiment will not affect the independent implementation of the first embodiment.
[0039] Specifically, the second embodiment of the present application provides a stent-type drug-device combination nanostructured nasal hemostatic device that is different in that it also includes the following features:
[0040] A flying wing 7 is provided between the connecting catheter 6 and the sensing airbag 4. When in use, the flying wing 7 is attached to the face with adhesive tape for fixing. The flying wing 7 is used to fix the position of the inflatable airbag 4 in the nasal cavity.
[0041] The working principle of this embodiment is as follows: the parts of this embodiment that are the same as those of the first embodiment will not be repeated. The difference from the first embodiment is that in this embodiment, a wing 7 is provided to fix the position of the inflatable airbag 4 in the nasal cavity.
[0042] How to use: Before removing, gently bend and close the wings 7 to avoid scratching the nasal cavity.
[0043] The above description is only an embodiment of the present invention, and does not limit the patent scope of the present invention. Any equivalent structure or equivalent process transformation made by using the contents of the specification and drawings of the present invention, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present invention.
Claims
1. A nanostructured nasal hemostatic device of a stent-type drug-device combination, comprising an inflatable airbag (4), characterized in that: The outer side of the inflatable airbag (4) is covered with a bracket (3), and the outer side of the bracket (3) is provided with a hemostatic gauze (1); A hemostatic sponge (2) is arranged between the hemostatic gauze (1) and the support (3).
2. The nanostructured nasal hemostatic device of a stent-type drug-device combination according to claim 1 is characterized by: One end of the inflatable airbag (4) is a plane, and the other end is an arc-shaped surface. A fixing ring (5) is fixed at the center of one end of the plane of the inflatable airbag (4). One end of a connecting conduit (6) is fixedly connected inside the fixing ring (5). One end of the connecting conduit (6) is fixedly connected to the inflatable airbag (4).
3. The nanostructured nasal hemostatic device of a stent-type drug-device combination according to claim 2 is characterized by: The other end of the connecting conduit (6) is fixedly connected to one end of the sensing airbag (8), and the other end of the sensing airbag (8) is provided with an inflation valve (9).
4. The nanostructured nasal hemostatic device of a stent-type drug-device combination according to claim 3 is characterized by: The inflation valve (9) is matched with a syringe (10).
5. The nanostructured nasal hemostatic device of a stent-type drug-device combination according to claim 4 is characterized by: The hemostatic gauze (1) is collagen hemostatic gauze, and the surface of the hemostatic gauze (1) is covered with antibacterial and anti-inflammatory drugs.
6. The nanostructured nasal hemostatic device of a stent-type drug-device combination according to claim 5 is characterized by: The bracket (3) is made of metal with shape memory properties.
7. The nanostructured nasal hemostatic device of a stent-type drug-device combination according to claim 6 is characterized by: The hemostatic sponge (2) is a degradable hemostatic sponge made of chitosan with a nanostructure and has the functions of absorbing blood and promoting blood coagulation.
8. The nanostructured nasal hemostatic device of a stent-type drug-device combination according to claim 7 is characterized by: A flying wing (7) is arranged between the connecting conduit (6) and the sensing airbag (8).